T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Boehringer Ingelheim
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
QuantumLeap Healthcare Collaborative
Hoffmann-La Roche
National Medical Research Radiological Centre of the Ministry of Health of Russia
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Chicago
City of Hope Medical Center
Hoffmann-La Roche
Dana-Farber Cancer Institute
Institut Curie
MedSIR
Daiichi Sankyo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hoffmann-La Roche
Hoffmann-La Roche
Cancer Trials Ireland
Dana-Farber Cancer Institute
University of Virginia
Population Health Research Institute
Jules Bordet Institute
Dana-Farber Cancer Institute
Jules Bordet Institute
Hoffmann-La Roche
University of Arizona
SOLTI Breast Cancer Research Group
N.N. Petrov National Medical Research Center of Oncology
Hoffmann-La Roche
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Academic and Community Cancer Research United
National Institutes of Health Clinical Center (CC)
Fondazione per la Medicina Personalizzata
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Hoffmann-La Roche
Shanghai Miracogen Inc.
Stanford University
Dana-Farber Cancer Institute
Hoffmann-La Roche
Academic and Community Cancer Research United
Hoffmann-La Roche
MedSIR
University of Texas Southwestern Medical Center
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Karolinska University Hospital